Tumor Necrosis Factor-blocking Agents for Children with Enthesitis-related Arthritis — Data from the Dutch Arthritis and Biologicals in Children Register, 1999–2010
M.H. Otten(Erasmus University Rotterdam), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), Marinka Twilt(University of Calgary), Nico Wulffraat(Utrecht University), R. ten Cate(Leiden University), Koert M. Dolman(Reade), Esther P A H Hoppenreijs(Radboud University Nijmegen), J. Merlijn van den Berg(Boston Children's Hospital), Femke H. M. Prince(Brigham and Women's Hospital), Wineke Armbrust, Simone Gorter(University Medical Center Groningen), Marion A. J. van Rossum(Reade), Y. Koopman-Keemink(Juliana Kinderziekenhuis), Joost F. Swart(Trinity College Dublin)
Cited by 73
Related Papers
Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome
|Nature Genetics|2000|951
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
|Annals of the Rheumatic Diseases|2008|220
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
|Arthritis & Rheumatism|1998|217
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study
|The Lancet Child & Adolescent Health|2019|214